Patents by Inventor Norihito Murayama
Norihito Murayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240127911Abstract: Conventionally, it has not been possible to easily know the user's blood sugar constitution type. It is possible to easily know the user's blood sugar constitution type using a blood sugar constitution determination device including: a storage unit that stores one or more pieces of question information that are used to judge a blood sugar constitution type and include a question regarding lifestyle; an output unit that outputs the one or more pieces of question information; an acceptance unit that accepts, from a user, answer information corresponding to the one or more pieces of question information; a processing unit that determines a blood sugar constitution type of the user, using the one or more pieces of answer information accepted by the acceptance unit; and an information output unit that outputs output information regarding the blood sugar constitution type.Type: ApplicationFiled: August 17, 2021Publication date: April 18, 2024Applicant: SUNTORY HOLDINGS LIMITEDInventors: Tomoaki Uchida, Norihito Murayama, Yuji Nonaka, Takeshi Kanamori
-
Publication number: 20230000829Abstract: The present invention aims to provide a composition for sleep improvement, which contains a highly safe substance as an active ingredient, and a method of improving sleep. The present invention relates to, for example, a composition for sleep improvement, which contains L-ergothioneine or a salt thereof as an active ingredient.Type: ApplicationFiled: October 7, 2020Publication date: January 5, 2023Applicant: SUNTORY HOLDINGS LIMITEDInventors: Makoto Katsube, Hiroshi Watanabe, Kenichi Wakabayashi, Norihito Murayama, Kosuke Suzuki, Yoshitaka Tatebayashi, Yoshiki Matsuda, Nobuyuki Ozawa, Takiko Shinozaki
-
Patent number: 9156817Abstract: Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.Type: GrantFiled: July 22, 2014Date of Patent: October 13, 2015Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Naohiro Takemoto, Kenji Murata, Norihito Murayama, Chikaomi Yamada
-
Publication number: 20150265680Abstract: The present invention provides a therapeutic agent for amyotrophic lateral sclerosis comprising a growth hormone secretagogue receptor (GHS-R) agonist or a pharmaceutically acceptable salt thereof as an active ingredient. An object of the present invention is to provide a pharmaceutical product for amyotrophic lateral sclerosis for which no effective drug exists. The therapeutic agent for amyotrophic lateral sclerosis of the present invention comprises a GHS-R agonist typified by ghrelin as an active ingredient and is administered to a recipient individual having amyotrophic lateral sclerosis with non-serious dysphagia. The individual may also be unresponsive or insufficiently responsive to an existing therapeutic agent for ALS.Type: ApplicationFiled: October 23, 2013Publication date: September 24, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Matsuo, Norihito Murayama, Mayumi Furuya
-
Patent number: 9139559Abstract: Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.Type: GrantFiled: February 5, 2014Date of Patent: September 22, 2015Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Naohiro Takemoto, Kenji Murata, Norihito Murayama, Chikaomi Yamada
-
Publication number: 20140336209Abstract: Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, —CO— or the like; and Q is a hydrogen atom or a phenyl group.Type: ApplicationFiled: July 22, 2014Publication date: November 13, 2014Inventors: Naohiro TAKEMOTO, Kenji MURATA, Norihito MURAYAMA, Chikaomi YAMADA
-
Publication number: 20140221409Abstract: Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, —CO— or the like; and Q is a hydrogen atom or a phenyl group.Type: ApplicationFiled: February 5, 2014Publication date: August 7, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Naohiro TAKEMOTO, Kenji MURATA, Norihito MURAYAMA, Chikaomi YAMADA
-
Patent number: 8685989Abstract: Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of of 0 to 5; X and Y are each a connected bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.Type: GrantFiled: May 29, 2012Date of Patent: April 1, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Naohiro Takemoto, Kenji Murata, Norihito Murayama, Chikaomi Yamada
-
Patent number: 8592435Abstract: Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, —CO— or the like; and Q is a hydrogen atom or a phenyl group.Type: GrantFiled: April 25, 2008Date of Patent: November 26, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Naohiro Takemoto, Kenji Murata, Norihito Murayama, Chikaomi Yamada
-
Publication number: 20120258978Abstract: Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.Type: ApplicationFiled: May 29, 2012Publication date: October 11, 2012Applicant: Daiichi Sankyo Company, LimitedInventors: Naohiro TAKEMOTO, Kenji MURATA, Norihito MURAYAMA, Chikaomi YAMADA
-
Publication number: 20100130739Abstract: Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, —CO— or the like; and Q is a hydrogen atom or a phenyl group.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Applicant: ASUBIO PHARMA CO., LTD.Inventors: Naohiro Takemoto, Kenji Murata, Norihito Murayama, Chikaomi Yamada
-
Publication number: 20060178401Abstract: The present invention relates to an amiophenoxyacetamide derivative of the formula (I): wherein R1 to R4 are, independent from each other, a hydrogen atom or an optionally substituted alkyl group; E1 is —NR4—; and E2 is an oxygen atom or —NR10—; Q is the group —X—Y-Q?, wherein X and Y are connecting bonds or X is an alkylene or alkenylene group and Y is selected from a group comprising C?O, NHC(?O), and C(?O)NH, and Q? is a hydrogen atom or a phenyl or pyridyl group which may be substituted; and pharmaceutically acceptable salts thereof. The present invention further relates to compositions comprising compounds of the formula (I) and methods of using said compounds for treating cerebral functional disorders and cerebral organic disorders.Type: ApplicationFiled: January 24, 2006Publication date: August 10, 2006Inventors: Naohiro Takemoto, Hirokazu Annoura, Norihito Murayama
-
Patent number: 7067533Abstract: The present invention relates to an aminophenoxyacetamide derivative of the formula (I): wherein R1 to R4 are, independent from each other, a hydrogen atom or an optionally substituted alkyl group; E1 is —NR4—; and E2 is an oxygen atom or —NR10—; Q is the group —X—Y-Q?, wherein X and Y are connecting bonds or X is an alkylene or alkenylene group and Y is selected from a group comprising C?O, NHC(?), and C(?O)NH, and Q? is a hydrogen atom or a phenyl or pyridyl group which may be substituted; and pharmaceutically acceptable salts thereof. The present invention further relates to compositions comprising compounds of the formula (I) and methods of using said compounds for treating cerebral functional disorders and cerebral organic disorders.Type: GrantFiled: April 13, 2001Date of Patent: June 27, 2006Assignee: Daiichi Asubio Pharma Co., Ltd.Inventors: Naohiro Takemoto, Hirokazu Annoura, Norihito Murayama
-
Publication number: 20030139447Abstract: There is provided an aminophenoxyacetamide derivative of the formula (I): wherein, R1 to R4 are, independent from each other, hydrogen atom; optionally substituted alkyl group; E1 is —NR4— and E2 is oxygen atom or —NR10; Q is group —X—Y—Q′ (X and Y are connecting bond; X is alkylene or alkenylene group, etc.; Y is selected from the groups consisting of C═O, NHC(═O), C(═O)NH, etc.; Q′ is hydrogen atom or pheny, pyridyl groups which may be substituted, etc.), or a pharmaceutically acceptable salt thereof. These compounds have neuroprotective effect by introducing the CalbindinD-28k, one of Ca2+-binding proteins.Type: ApplicationFiled: December 12, 2001Publication date: July 24, 2003Inventors: Naohiro Takemoto, Hirokazu Annoura, Norihito Murayama